213 related articles for article (PubMed ID: 7636538)
1. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
Rowinsky EK; Noe DA; Grochow LB; Sartorious SE; Bowling MK; Chen TL; Lubejko BG; Kaufmann SH; Donehower RC
J Clin Oncol; 1995 Aug; 13(8):1975-84. PubMed ID: 7636538
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
3. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.
Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP
Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415
[TBL] [Abstract][Full Text] [Related]
4. A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer.
Pelley R; Ganapathi R; Wood L; Rybicki L; McLain D; Budd GT; Peereboom D; Olencki T; Bukowski RM
Cancer Chemother Pharmacol; 2000; 46(3):251-4. PubMed ID: 11021744
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.
Dees EC; Rowinsky EK; Noe DA; O'Reilly S; Adjei AA; Elza-Brown K; Donehower RC
Invest New Drugs; 2003 Feb; 21(1):75-84. PubMed ID: 12795532
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Plaxe SC; Blessing JA; Olt G; Husseinzadah N; Lentz SS; DeGeest K; Valea FA
Cancer Chemother Pharmacol; 2002 Aug; 50(2):151-4. PubMed ID: 12172981
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.
Galanis E; Buckner JC; Maurer MJ; Reid JM; Kuffel MJ; Ames MM; Scheithauer BW; Hammack JE; Pipoly G; Kuross SA
Invest New Drugs; 2005 Oct; 23(5):495-503. PubMed ID: 16133802
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma.
Zalupski MM; Philip PA; LoRusso P; Shields AF
Cancer Chemother Pharmacol; 1997; 40(3):225-7. PubMed ID: 9219505
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study.
Plaxe SC; Blessing JA; Lucci JA; Hurteau JA
Invest New Drugs; 2001; 19(1):77-80. PubMed ID: 11291835
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer.
Adjei AA; Reid JM; Erlichman C; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Ruben S; Boemer SA; Atherton P; Ames MM; Kaufmann SH
Invest New Drugs; 2002 Aug; 20(3):297-304. PubMed ID: 12201492
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
Plaxe SC; Blessing JA; Bookman MA; Creasman WT
Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.
Villalona-Calero MA; Eder JP; Toppmeyer DL; Allen LF; Fram R; Velagapudi R; Myers M; Amato A; Kagen-Hallet K; Razvillas B; Kufe DW; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2001 Feb; 19(3):857-69. PubMed ID: 11157040
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma.
Zalupski MM; Shields AF; Philip PA; Kraut M; LoRusso P; Heilbrun LK; Vaitkevicius V
Invest New Drugs; 1998; 16(1):93-6. PubMed ID: 9740550
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study.
Plaxe SC; Blessing JA; Morgan MA; Carlson J;
Am J Clin Oncol; 2002 Feb; 25(1):45-7. PubMed ID: 11823695
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
O'Reilly S; Fleming GF; Barker SD; Walczak JR; Bookman MA; McGuire WP; Schilder RJ; Alvarez RD; Armstrong DK; Horowitz IR; Ozols RF; Rowinsky EK
J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
[TBL] [Abstract][Full Text] [Related]
20. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
